Bicara Therapeutics BCAX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$56.21M-52.6% | -$37.39M-78.4% | -$36.33M-108% | -$27.39M-60.6% | -$36.85M-195% | ||
| $44K+132% | $43K+187% | $24K+60.0% | $19K+46.2% | $19K+46.2% | ||
| $5.86M+69.7% | $4.45M+39.9% | $3.61M+77.9% | $3.49M+236% | $3.45M+201% | ||
| -$2.09M+49.2% | -$839K-105% | $0-100% | -$627K— | -$4.12M-1,851% | ||
| $273K+97.8% | —— | $249K+266% | $211K+220% | $138K+112% | ||
| -$270K-83.7% | -$292K-200% | -$317K-340% | -$176K-148% | -$147K-116% | ||
| -$37.51M-33.5% | -$23.89M+20.5% | -$29.25M-69.8% | -$25.59M-98.3% | -$28.11M-92.7% | ||
| $60K— | $238K+495% | $42K+425% | $0-100% | $0-100% | ||
| $101M— | —— | —— | —— | $0— | ||
| $100.94M— | -$82.33M-205,730% | -$236.12M— | $0— | $0-100% | ||
| $161.76M— | $29.5M— | -$595K-100% | $595K-55.3% | $0-100% | ||
| $163.35M+35,410% | $31.23M— | $436K-99.9% | $135K-81.6% | $460K+236% | ||
| $226.78M+920% | -$74.99M-216% | -$264.93M-184% | -$25.46M-109% | -$27.65M-92.1% | ||
| $0-100% | —— | $167K— | $52K— | $72K+7,100% | ||
| -$338K— | -$269K— | —— | —— | $0— | ||
| $44K+132% | $43K+187% | $24K+60.0% | $19K+46.2% | $19K+46.2% | ||
| -$270K-83.7% | -$292K-200% | -$317K-340% | -$176K-148% | -$147K-116% | ||
| -$2.09M+49.2% | -$839K-105% | $0-100% | -$627K— | -$4.12M-1,851% | ||
| $273K+97.8% | —— | $249K+266% | $211K+220% | $138K+112% | ||
| —— | $223.75K+1,262% | $223.75K+1,262% | $223.75K+1,262% | $223.75K+1,262% | ||
| $101M— | —— | —— | —— | $0— | ||
| $190K— | —— | $0-100% | $0— | $0— | ||
| -$37.57M-33.7% | -$24.12M+19.8% | -$29.29M-70.0% | -$25.59M-98.0% | -$28.11M-92.6% | ||
| -$37.57M-33.7% | -$24.12M+19.8% | -$29.29M-70.0% | -$25.59M-98.0% | -$28.11M-92.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Bicara Therapeutics's cash flow data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.